Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tumor antigen peptide-loaded myeloid dendritic cell product
- Development stage
- Phase 2
- Lead developer
- Radboud University Medical Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
The tumor antigen peptide-loaded myeloid dendritic cell product is an investigational autologous cellular immunotherapy developed by Radboud University Medical Center. It consists of naturally derived myeloid dendritic cells (mDCs) isolated from the patient's blood and loaded ex vivo with tumor-associated antigen (TAA) peptides. This dendritic cell vaccine is designed to prime and activate tumor-specific CD8+ cytotoxic T cells and CD4+ helper T cells to target and eliminate prostate cancer cells. It is currently being evaluated in a randomized phase IIa clinical trial (NCT02692976) for patients with chemo-naive metastatic castration-resistant prostate cancer (mCRPC), where its safety, immunogenicity, and clinical efficacy are being compared to plasmacytoid dendritic cell (pDC) products and combined mDC+pDC formulations.
- Other names
- mDC vaccinemyeloid dendritic cell vaccineautologous myeloid dendritic cells loaded with TAA peptides
02
Targets
CD28 (Cluster of Differentiation 28)MHC II (Major histocompatibility complex class II receptor)TAA/Neoantigen (Tumor-associated antigen and neoantigen peptide)
Beyond the preview
Go deeper on tumor antigen peptide-loaded myeloid dendritic cell product.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tumor antigen peptide-loaded myeloid dendritic cell product.